Promising data from #ESMO26 Presidential Symposium I: INTerpath-001 showed a 42% reduction in recurrence or death with individualized mRNA neoantigen therapy + pembrolizumab vs pembrolizumab alone in resected stage IIB–IV melanoma (HR 0.58; p<0.001). OS data remain immature.